此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

补充5-甲基四氢叶酸对哺乳期产妇健康及一碳代谢的影响 (OCMS)

2026年11月10日 更新者:Fundació Sant Joan de Déu

5-甲基四氢叶酸补充对哺乳期母体健康和一碳代谢的影响

This double-blind, randomized, placebo-controlled parallel trial evaluates the effects of maternal 5-methyltetrahydrofolate (5-MTHF) supplementation during breastfeeding. Thirty-six lactating mother-infant dyads will be randomized (1:1) to receive 5-MTHF or placebo for 6 weeks, stratified by infant sex and mode of delivery. Tolerability and adverse events will be monitored.

Pre- and post-intervention assessments include breast milk one-carbon metabolites and oligosaccharides; maternal plasma one-carbon metabolites and metabolic health markers. Maternal mental health will be evaluated using the SCL-90-R questionnaire. A follow-up visit at 4 months will reassess infant anthropometry and microbiome outcomes.

研究概览

研究类型

介入性

注册 (估计的)

36

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Marta Ramon Krauel, MD PhD
  • 电话号码:Ext. 71263 (+34) 93 280 40 00
  • 邮箱:marta.ramon@sjd.es

学习地点

    • Barcelona
      • Barcelona、Barcelona、西班牙、08950
        • 招聘中
        • Hospital Sant Joan de Deu
        • 接触:
      • Barcelona、Barcelona、西班牙、08950
        • 尚未招聘
        • Hospital Sant Joan de Déu
        • 接触:
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 42年 (成人)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Maternal age between 18 and 42 years
  • Gestational age at birth ≥ 37 weeks.
  • Exclusive breastfeeding at enrollment.
  • Infant age 0-1 months

Exclusion Criteria:

  • Multiple pregnancy
  • Presence of disease or malformations in the infant.
  • Weight-Standard Deviation Score < -1 at enrollment.
  • Use of folate-containing multivitamin supplements during breastfeeding

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Placebo

Placebo

Matching placebo administered daily for 6 weeks during lactation.

实验性的:5-MTHF Supplementation

Dietary Supplement (5-MTHF)

Oral supplementation with 5-MTHF (800 µg) administered daily for 6 weeks during lactation.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of Adverse Events
大体时间:Baseline, 6 weeks, 4 months

Treatment safety and tolerability will be evaluated by assessing differences in the incidence of potential adverse events between groups, focusing on gastrointestinal symptoms.

Baseline, 6 weeks, 4 months
Change in breast milk 5-MTHF concentration
大体时间:Baseline, 6 weeks

Change in breast milk 5-MTHF concentration measured with liquid chromatography coupled to mass spectrometry (LC-MS) from Baseline to 6 weeks.

Baseline, 6 weeks

次要结果测量

结果测量
措施说明
大体时间
Change in plasma 5-MTHF concentration
大体时间:Baseline, 6 weeks

Change in maternal plasma 5-MTHF concentration measured with liquid chromatography coupled to mass spectrometry (LC-MS) from Baseline to 6 weeks.

Baseline, 6 weeks
Change in breast milk one-carbon metabolite concentration
大体时间:Baseline, 6 weeks

Change in breast milk one-carbon-related metabolites (choline, methionine, SAM, SAH, homocysteine, cystathionine, folic acid, betaine) from Baseline to 6 weeks.

Baseline, 6 weeks
Change in plasma one-carbon metabolite concentration
大体时间:Baseline, 6 weeks

Change in plasma one-carbon-related metabolites (choline, methionine, SAM, SAH, homocysteine, cystathionine, folic acid, betaine) from Baseline to 6 weeks.

Baseline, 6 weeks
Change in Human Milk Oligosaccharide (HMO) concentration
大体时间:Baseline, 6 weeks

Change in HMO concentrations between Baseline and 6 weeks

Baseline, 6 weeks
Change in Maternal Plasma Glucose Concentration
大体时间:Baseline, 6 weeks

Change in maternal blood glucose levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Plasma Glycated Hemoglobin (HbA1c) Concentration
大体时间:Baseline, 6 weeks

Change in maternal blood glycated hemoglobin (HbA1c) between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Plasma Insulin Concentration
大体时间:Baseline, 6 weeks

Change in maternal blood insulin levels between Baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Plasma Triglyceride (TAG) Concentration
大体时间:Baseline, 6 weeks

Change in maternal blood triglyceride (TAG) levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Blood Total Cholesterol Concentration
大体时间:Baseline, 6 weeks

Change in maternal blood total Cholesterol levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Blood LDL Cholesterol Concentration
大体时间:Baseline, 6 weeks

Change in maternal low-density lipoprotein (LDL) cholesterol levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Blood HDL Cholesterol Concentration
大体时间:Baseline, 6 weeks

Change in maternal high-density lipoprotein (HDL) cholesterol levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Blood Alanine Aminotransferase (ALT) Levels
大体时间:Baseline, 6 weeks

Change in maternal alanine aminotransferase (ALT) levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Blood Aspartate Aminotransferase (AST) Levels
大体时间:Baseline, 6 weeks

Change in maternal aspartate aminotransferase (AST) levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Maternal Blood Gamma-Glutamyl Transferase (GGT) Levels
大体时间:Baseline, 6 weeks

Change in maternal gamma-glutamyl transferase (GGT) levels between baseline and 6 weeks.

Baseline, 6 weeks
Change in Symptom Checklist-90-Revised (SCL-90-R) scale
大体时间:Baseline, 3 weeks

The SCL-90-R is a 90-item self-report questionnaire assessing psychological symptoms over the past week, with a range of 0-90 across 9 dimenions: Somatization, Obsessive-compulsive, Interpersonal sensitivity, Depression, Anxiety, Hostility, Phobic anxiety, Paranoid ideation, Psychoticism. Higher scores indicate worse outcome.

Baseline, 3 weeks
Change in infant BMI z-score
大体时间:Baseline, 6 weeks

We will measure infant body weight, length, and head circumference to calculate BMI z-scores according to WHO growth standards, and changes between baseline, 6 weeks and 4 months will be assessed.

Baseline, 6 weeks

其他结果措施

结果测量
措施说明
大体时间
Maternal and infant gut microbiome composition
大体时间:Baseline, 6 weeks

Bacterial DNA will be isolated from infant and maternal fecal samples and sequenced to obtain microbiome composition.

Baseline, 6 weeks
Maternal plasma and breast milk metabolomic profile
大体时间:Baselina, 6 weeks

The metabolomic profile will be obtained with the Biocrates Quant 1000 kit from plasma and breast milk samples.

Baselina, 6 weeks
Milk imprinted protein levels
大体时间:Baseline, 6 weeks

Imprinted proteins in human milk samples will be analyzed by ELISA.

Baseline, 6 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Carles Lerin, PhD、Fundació Sant Joan de Déu

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年4月15日

初级完成 (估计的)

2026年12月31日

研究完成 (估计的)

2027年4月30日

研究注册日期

首次提交

2026年3月19日

首先提交符合 QC 标准的

2026年3月27日

首次发布 (实际的)

2026年4月2日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅